Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 60

Sort by

Sort Order Select

Meeting Abstracts

1626-P: Activation of Cardiac Mitochondrial Akt1 Enhanced Myocardial Fatty Acid Utilization, Protected against Diabetic Cardiomyopathy, and Improved Whole Body Fat Distribution

ALBERT TA, YUMAY CHEN, JUNFENG LI, ESAM SALEM, PING H. WANG

Diabetes 2023;72(Supplement_1):1626-P

https://doi.org/10.2337/db23-1626-P

Published: 20 June 2023

View article titled, 1626-P: Activation of Cardiac Mitochondrial Akt1 Enhanced Myocardial Fatty Acid Utilization, Protected against Diabetic Cardiomyopathy, and Improved Whole Body Fat Distribution

Journal Articles

Gut Microbiome: An Effector of Dietary Nitrate That Inhibits Cardiometabolic Disease?

Michinari Nakamura

Diabetes 2023;72(7):835–837

https://doi.org/10.2337/dbi23-0008

Published: 20 June 2023

View article titled, Gut Microbiome: An Effector of Dietary Nitrate That Inhibits Cardiometabolic Disease?

Meeting Abstracts

1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

JAVED BUTLER, STEFANO DEL PRATO, JUSTIN EZEKOWITZ, NASRIEN E. IBRAHIM, CAROLYN S. LAM, RICCARDO PERFETTI, JULIO ROSENSTOCK, W.H. WILSON TANG, ALESSIA URBINATI, FAIEZ ZANNAD, JAMES L. JANUZZI

Diabetes 2023;72(Supplement_1):1238-P

https://doi.org/10.2337/db23-1238-P

Published: 20 June 2023

View article titled, 1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

Meeting Abstracts

450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

JAVED BUTLER, STEFANO DEL PRATO, JUSTIN EZEKOWITZ, NASRIEN E. IBRAHIM, CAROLYN S. LAM, RICCARDO PERFETTI, JULIO ROSENSTOCK, W.H. WILSON TANG, ALESSIA URBINATI, FAIEZ ZANNAD, JAMES L. JANUZZI, JR.

Diabetes 2023;72(Supplement_1):450-P

https://doi.org/10.2337/db23-450-P

Published: 20 June 2023

View article titled, 450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

Meeting Abstracts

568-P: Study of the Effect of PPARß/δ Activation on Diabetic Cardiomyopathy

ADEL ROSTAMI

Diabetes 2023;72(Supplement_1):568-P

https://doi.org/10.2337/db23-568-P

Published: 20 June 2023

View article titled, 568-P: Study of the Effect of PPARß/δ Activation on Diabetic Cardiomyopathy

Journal Articles

Erratum. TRB3 Gene Silencing Alleviates Diabetic Cardiomyopathy in a Type 2 Diabetic Rat Model. Diabetes 2011;60:2963–2974

Yun Ti, Guo-lu Xie, Zhi-hao Wang, Xiao-lei Bi, Wen-yuan Ding, Jia Wang, Gui-hua Jiang, Pei-li Bu, Yun Zhang, Ming Zhong, Wei Zhang

Diabetes 2023;72(6):820

https://doi.org/10.2337/db23-er06a

Published: 18 April 2023

View article titled, Erratum. <em>TRB3</em> Gene Silencing Alleviates Diabetic Cardiomyopathy in a Type 2 Diabetic Rat Model. Diabetes 2011;60:2963–2974

Meeting Abstracts

355-OR: WATCH-DM Identifies Diabetic Cardiomyopathy: A Multicohort Analysis

MATTHEW W. SEGAR, KERSHAW PATEL, MUTHIAH VADUGANATHAN, ALVIN CHANDRA, DUWAYNE L. WILLETT, AMBARISH PANDEY

Diabetes 2022;71(Supplement_1):355-OR

https://doi.org/10.2337/db22-355-OR

Published: 01 June 2022

View article titled, 355-OR: WATCH-DM Identifies Diabetic Cardiomyopathy: A Multicohort Analysis

Meeting Abstracts

207-LB: Aldose Reductase Inhibition by AT-001 Limits Diastolic Dysfunction and Adverse Remodelling in Diabetic Cardiomyopathy

QUTUBA G. KARWI, KESHAV GOPAL, SEYED AMIRHOSSEIN TABATABAEI DAKHILI, CORY S. WAGG, LIYAN ZHANG, QIUYU SUN, CHRISTINA T. SAED, SAI PANIDARAPU, RICCARDO PERFETTI, RAVICHANDRAN RAMASAMY, JOHN R. USSHER, GARY LOPASCHUK

Diabetes 2022;71(Supplement_1):207-LB

https://doi.org/10.2337/db22-207-LB

Published: 01 June 2022

View article titled, 207-LB: Aldose Reductase Inhibition by AT-001 Limits Diastolic Dysfunction and Adverse Remodelling in Diabetic Cardiomyopathy

Meeting Abstracts

1090-P: Prevalence of Diabetic Cardiomyopathy in an Electronic Health Record–Based Cohort

MATTHEW W. SEGAR, KERSHAW PATEL, MUTHIAH VADUGANATHAN, ALVIN CHANDRA, DUWAYNE L. WILLETT, AMBARISH PANDEY

Diabetes 2022;71(Supplement_1):1090-P

https://doi.org/10.2337/db22-1090-P

Published: 01 June 2022

View article titled, 1090-P: Prevalence of Diabetic Cardiomyopathy in an Electronic Health Record–Based Cohort

Meeting Abstracts

971-P: Prevalence of Diabetic Cardiomyopathy in Real-World Practice: A Longitudinal Cohort Study

IWONA SWIATKIEWICZ, NEEJA T. PATEL, PAM R. TAUB

Diabetes 2021;70(Supplement_1):971-P

https://doi.org/10.2337/db21-971-P

Published: 01 June 2021

View article titled, 971-P: Prevalence of Diabetic Cardiomyopathy in Real-World Practice: A Longitudinal Cohort Study

Meeting Abstracts

978-P: Prevalence of Diabetic Cardiomyopathy in Adults with Diabetes or Prediabetes and Its Association with the Risk of Overt Heart Failure: A Multicohort Analysis

MATTHEW W. SEGAR, KERSHAW PATEL, NITIN KONDAMUDI, AMBARISH PANDEY

Diabetes 2021;70(Supplement_1):978-P

https://doi.org/10.2337/db21-978-P

Published: 01 June 2021

View article titled, 978-P: Prevalence of Diabetic Cardiomyopathy in Adults with Diabetes or Prediabetes and Its Association with the Risk of Overt Heart Failure: A Multicohort Analysis

Meeting Abstracts

362-P: Punicalagin Promotes Mitochondrial Fusion and Alleviates Diabetic Cardiomyopathy via Regulating PTP1B-Stat3-Opa1 Pathway

MINGGE DING, MAN LI, FENG FU, CHAOYANG LIU

Diabetes 2021;70(Supplement_1):362-P

https://doi.org/10.2337/db21-362-P

Published: 01 June 2021

View article titled, 362-P: Punicalagin Promotes Mitochondrial Fusion and Alleviates Diabetic Cardiomyopathy via Regulating PTP1B-Stat3-Opa1 Pathway

Meeting Abstracts

379-P: Aldose Reductase Inhibition by AT-001 Prevents Diabetic Cardiomyopathy via Reducing Myocardial Fatty Acid Oxidation Rates

KESHAV GOPAL, QUTUBA G. KARWI, SEYED AMIRHOSSEIN TABATABAEI DAKHILI, CORY S. WAGG, RICCARDO PERFETTI, RAVICHANDRAN RAMASAMY, JOHN R. USSHER, GARY LOPASCHUK

Diabetes 2021;70(Supplement_1):379-P

https://doi.org/10.2337/db21-379-P

Published: 01 June 2021

View article titled, 379-P: Aldose Reductase Inhibition by AT-001 Prevents Diabetic Cardiomyopathy via Reducing Myocardial Fatty Acid Oxidation Rates

Meeting Abstracts

1043-P: Diabetic Cardiomyopathy: A Systematic Analysis of Epidemiological Studies

RICCARDO PERFETTI, SHOSHANA SHENDELMAN

Diabetes 2021;70(Supplement_1):1043-P

https://doi.org/10.2337/db21-1043-P

Published: 01 June 2021

View article titled, 1043-P: Diabetic Cardiomyopathy: A Systematic Analysis of Epidemiological Studies

Journal Articles

Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice

Huimei Zang, Weiwei Wu, Lei Qi, Wenbin Tan, Prakash Nagarkatti, Mitzi Nagarkatti, Xuejun Wang, Taixing Cui

Diabetes 2020;69(12):2720–2734

https://doi.org/10.2337/db19-1176

Published: 18 September 2020

View article titled, Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice

Meeting Abstracts

458-P: Resveratrol Attenuates Diabetic Cardiomyopathy by Inhibiting Asymmetric Dimethylarginine-Induced PGC-1a Acetylation

YAN XIONG, WEI-JIN FANG, ZHI-MIN HE

Diabetes 2020;69(Supplement_1):458-P

https://doi.org/10.2337/db20-458-P

Published: 01 June 2020

View article titled, 458-P: Resveratrol Attenuates Diabetic Cardiomyopathy by Inhibiting Asymmetric Dimethylarginine-Induced PGC-1a Acetylation

Meeting Abstracts

442-P: Comparative Study of the Effects of GLP-1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms

ELSAYED A. EID, ABDELAZIZ HUSSEIN, LASHIN LASHIN, MEDHAT TAHA

Diabetes 2020;69(Supplement_1):442-P

https://doi.org/10.2337/db20-442-P

Published: 01 June 2020

View article titled, 442-P: Comparative Study of the Effects of GLP-1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms

Meeting Abstracts

409-P: Engineered Cardiac Tissues: A Novel In Vitro Model to Investigate the Pathophysiology of Diabetic Cardiomyopathy

XIANG WANG, YANG ZHENG, BRADLEY B. KELLER, LU CAI

Diabetes 2020;69(Supplement_1):409-P

https://doi.org/10.2337/db20-409-P

Published: 01 June 2020

View article titled, 409-P: Engineered Cardiac Tissues: A Novel In Vitro Model to Investigate the Pathophysiology of Diabetic Cardiomyopathy

Meeting Abstracts

451-P: Proteome Profiling in Rat Cardiomyoblasts: Understanding Diabetic Cardiomyopathy

BERND STRATMANN, BRITTA EGGERS, YVONNE MATTERN, KATRIN MARCUS, DIETHELM TSCHOEPE

Diabetes 2020;69(Supplement_1):451-P

https://doi.org/10.2337/db20-451-P

Published: 01 June 2020

View article titled, 451-P: Proteome Profiling in Rat Cardiomyoblasts: Understanding Diabetic Cardiomyopathy

Meeting Abstracts

186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

RICCARDO PERFETTI, FRANCESCA C. LAWSON, JULIO ROSENSTOCK, JAMES JANUZZI, JR., SHOSHANA SHENDELMAN, STELLA WANG, AMEEN F. GHANNAM

Diabetes 2020;69(Supplement_1):186-OR

https://doi.org/10.2337/db20-186-OR

Published: 01 June 2020

View article titled, 186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

NARROW

1626-P: Activation of Cardiac Mitochondrial Akt1 Enhanced Myocardial Fatty Acid Utilization, Protected against Diabetic Cardiomyopathy, and Improved Whole Body Fat Distribution

Gut Microbiome: An Effector of Dietary Nitrate That Inhibits Cardiometabolic Disease?

1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

568-P: Study of the Effect of PPARß/δ Activation on Diabetic Cardiomyopathy

Erratum. TRB3 Gene Silencing Alleviates Diabetic Cardiomyopathy in a Type 2 Diabetic Rat Model. Diabetes 2011;60:2963–2974

355-OR: WATCH-DM Identifies Diabetic Cardiomyopathy: A Multicohort Analysis

207-LB: Aldose Reductase Inhibition by AT-001 Limits Diastolic Dysfunction and Adverse Remodelling in Diabetic Cardiomyopathy

1090-P: Prevalence of Diabetic Cardiomyopathy in an Electronic Health Record–Based Cohort

971-P: Prevalence of Diabetic Cardiomyopathy in Real-World Practice: A Longitudinal Cohort Study

978-P: Prevalence of Diabetic Cardiomyopathy in Adults with Diabetes or Prediabetes and Its Association with the Risk of Overt Heart Failure: A Multicohort Analysis

362-P: Punicalagin Promotes Mitochondrial Fusion and Alleviates Diabetic Cardiomyopathy via Regulating PTP1B-Stat3-Opa1 Pathway

379-P: Aldose Reductase Inhibition by AT-001 Prevents Diabetic Cardiomyopathy via Reducing Myocardial Fatty Acid Oxidation Rates

1043-P: Diabetic Cardiomyopathy: A Systematic Analysis of Epidemiological Studies

Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice

458-P: Resveratrol Attenuates Diabetic Cardiomyopathy by Inhibiting Asymmetric Dimethylarginine-Induced PGC-1a Acetylation

442-P: Comparative Study of the Effects of GLP-1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms

409-P: Engineered Cardiac Tissues: A Novel In Vitro Model to Investigate the Pathophysiology of Diabetic Cardiomyopathy

451-P: Proteome Profiling in Rat Cardiomyoblasts: Understanding Diabetic Cardiomyopathy

186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only